The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors Following In Vivo Administration
Abstract
To evaluate the contribution of the innate immune component of host defense in clearing the genome of adenovirus (Ad) vectors following in vivo administration, the Ad vectors AdCMV.βgal (expressing β-galactosidase) or AdCMV.Null (expressing no gene) were administered intravenously to immunocompetent or immunodeficient mice, and the amount of vector genome was quantified in the liver. Strikingly, 90% of vector DNA was eliminated within 24 hr. There was no increase in vector DNA in other tissues over this period, suggesting that rapid clearance of vector genome resulted from local degradation. After 24 hr, vector elimination was slow, with only 9% of the initial amount of vector genome cleared over the subsequent 3 weeks. Importantly, early phase (0–24 hr) elimination of vector DNA was independent of the transgene and similar in immunocompetent and nude animals. These observations suggest two phases of Ad vector elimination: a previously recognized late, immune-related elimination, and the early, innate immune elimination described in the present study. The early phase of vector loss is, by far, the dominant mechanism, an observation that has implications in developing strategies to maintain persistent expression of the newly transferred gene following in vivo gene therapy. Adaptive, virus-specific immune responses are thought to be responsible for the lack of persistence of the newly transferred adenovirus (Ad) genome following in vivo administration. The present study demonstrates that innate immune mechanisms also contribute significantly for the loss of vector genome over time. Following intravenous administration, 90% of the vector genome was eliminated from mouse liver within the first 24 hr. This loss was independent of dose, transgene, and was also seen in immunodeficient animals. The subsequent loss of vector genome was much slower, demonstrating that the early phase of vector elimination is the dominant mechanism. Circumventing these innate immune processes might be helpful in developing strategies to prevent loss of vector genome and achieve persistent expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
The Instructive Role of Innate Immunity in the Acquired Immune Response
Fearon, D. T., & Locksley, R. M. (1996) · Science · doi:10.1126/science.272.5258.50 · Cited by 1,719
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032
Transfer of Genes to Humans: Early Lessons and Obstacles to Success
Crystal, R. G. (1995) · Science · doi:10.1126/science.270.5235.404 · Cited by 1,000
Self-citationAdenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo
Rosenfeld, M. A., Siegfried, W., Yoshimura, K., Yoneyama, K., Fukayama, M., Stier, L. E., Pääkkö, P. K., Gilardi, P., Stratford-Perricaudet, L. D., Perricaudet, M., et al. (1991) · Science · doi:10.1126/science.2017680 · Cited by 737
Self-citationYang, Y., Ertl, H. C. J., & Wilson, J. M. (1994) · Immunity · doi:10.1016/1074-7613(94)90074-4 · Cited by 611
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Herz, J., & Gerard, R. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2812 · Cited by 517
Engelhardt, J. F., Ye, X., Doranz, B., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6196 · Cited by 470
Yang, Y., Nunes, F. A., Berencsi, K., Gönczöl, E., Engelhardt, J. F., & Wilson, J. M. (1994) · Nature Genetics · doi:10.1038/ng0794-362 · Cited by 450
Cited by
Rosengart, T. K., Lee, L. Y., Patel, S. R., Sanborn, T. A., Parikh, M., Bergman, G. W., Hachamovitch, R., Szulc, M., Kligfield, P. D., Okin, P. M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.5.468 · Cited by 656
Self-citationImmune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
Molecular basis of the inflammatory response to adenovirus vectors
Liu, Q., & Muruve, D. A. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302036 · Cited by 429
Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7478-7491.2005 · Cited by 427
Blood clearance rates of adenovirus type 5 in mice
Alemany, R., Suzuki, K., & Curiel, D. T. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2605 · Cited by 413
Lieber, A., He, C. Y., Meuse, L., Schowalter, D., Kirillova, I., Winther, B., & Kay, M. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8798-8807.1997 · Cited by 412
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409
The Innate Immune Response to Adenovirus Vectors
Muruve, D. A. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1157 · Cited by 407
Zhang, Y., Chirmule, N., Gao, G.-P., Qian, R., Croyle, M., Joshi, B., Tazelaar, J., & Wilson, J. M. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0329 · Cited by 376
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 366
Morsy, M. A., Gu, M., Motzel, S., Zhao, J., Lin, J., Su, Q., Allen, H., Franlin, L., Parks, R. J., Graham, F. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7866 · Cited by 365
Tao, N., Gao, G.-P., Parr, M., Johnston, J., Baradet, T., Wilson, J. M., Barsoum, J., & Fawell, S. E. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0227 · Cited by 321
Gutless adenovirus: last-generation adenovirus for gene therapy
Alba, R., Bosch, A., & Chillon, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302612 · Cited by 303
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
Alemany, R., & Curiel, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301515 · Cited by 294
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Wu, J. C., Sundaresan, G., Iyer, M., & Gambhir, S. S. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0460 · Cited by 273
In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted
Lusky, M., Christ, M., Rittner, K., Dieterle, A., Dreyer, D., Mourot, B., Schultz, H., Stoeckel, F., Pavirani, A., & Mehtali, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2022-2032.1998 · Cited by 273
Gordon, Y. J., Huang, L. C., Romanowski, E. G., Yates, K. A., Proske, R. J., & McDermott, A. M. (2005) · Current Eye Research · doi:10.1080/02713680590934111 · Cited by 252
Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239
Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
Innate immunity to adenovirus: lessons from mice
Atasheva, S., Yao, J., & Shayakhmetov, D. M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13696 · Cited by 87
Mukherjee, J., Dmitriev, I., Debatis, M., Tremblay, J. M., Beamer, G., Kashentseva, E. A., Curiel, D. T., & Shoemaker, C. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106422 · Cited by 37
Metadata
- Authors
- Worgall, S., Wolff, G., Falck-Pedersen, E., & Crystal, R. G.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1997-01
- Volume
- 8
- Issue
- 1
- Pages
- 37-44
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2017614842
- Cited by
- 491
- References
- 34
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.